Skip to main content
Livermore
Livermore
中文EN

Spruce Biosciences, Inc.

SPRB
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001683553

No open-market purchases or sales by Spruce Biosciences, Inc. insiders were filed in the last 90 days; 65 institutions reported holding it in 13F filings for Q2 2026, worth $116.3M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Spruce Biosciences, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Spruce Biosciences, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Spruce Biosciences, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Quartel Adrian WChief Medical Officer–Jul 29, 20261
Szwarcberg Javier B.CHIEF EXECUTIVE OFFICER19,270Jul 9, 20266
Spiegelman Daniel KDirector–May 26, 20262
Grey Michael GExecutive Chairman–May 26, 20262
Simpson Camilla VDirector–May 26, 20262
Barretto-Ko PercivalDirector–May 26, 20262
Walbert KeliDirector–May 26, 20262
Hooks Corwin DaleChief Commercial Officer–Mar 9, 20261
Ways KirkInterim Chief Medical Officer1,250Jan 21, 20261
Gharib Samir M.PRESIDENT AND CFO8,263Dec 17, 20254
Parkman Healthcare Partners LLC10% Owner1,050IndirectOct 15, 20252
Martinez Gregory10% Owner1,050IndirectOct 15, 20251
Aynechi TibaDirector–Jul 24, 20250
Muralidhar BaliDirector–Jul 24, 20250
Charlton Ralph William IIICHIEF MEDICAL OFFICER161,339Dec 20, 20240
Novo Holdings A/S10% Owner2,550,000Mar 25, 20240
O'Donnell NiallDirector1,326,305IndirectMay 26, 20230
Chaya Moghrabi DinaDirector–May 27, 20220
Dias SubaweerageChief Medical Officer–Dec 20, 20210
King RichardChief Executive Officer2,230Jul 6, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Oct 15, 2025 (view filing)4:32 PM ETOct 69 daysLateParkman Healthcare Partners LLC and 1 other10% OwnerPPurchaseCommon Stock, $0.001 par value per share+256$17.91+$4.59K+24.4%1.31K after
Oct 15, 2025 (view filing)4:32 PM ETOct 69 daysLateParkman Healthcare Partners LLC and 1 other10% OwnerSSaleCommon Stock, $0.001 par value per share−257$19.14−$4.92K−19.7%1.05K after2 lots
Oct 8, 2025 (view filing)Oct 62 daysParkman Healthcare Partners LLC10% OwnerPPurchaseCommon Stock, $0.001 par value per share+256$17.91+$4.58K+24.4%1.31K after
Oct 8, 2025 (view filing)Oct 62 daysParkman Healthcare Partners LLC10% OwnerSSaleCommon Stock, $0.001 par value per share−257$19.15−$4.92K−19.7%1.05K after2 lots
Mar 25, 2024 (view filing)Mar 214 daysNovo Holdings A/S10% OwnerSSale−465.0K$0.75−$348.8K−15.4%2.55M after
Mar 20, 2024 (view filing)Mar 18-202 daysNovo Holdings A/S10% OwnerSSale−1.79M$0.7587−$1.36M−37.3%3.02M after3 lots
Mar 18, 2024 (view filing)Mar 144 daysNovo Holdings A/S10% OwnerSSale−1.91M$0.89−$1.70M−28.4%4.81M after
May 16, 2023 (view filing)Feb 1689 daysLateO'Donnell NiallDirectorPPurchase+630.4K$3.17+$2.00M+90.6%1.33M after
May 16, 2023 (view filing)Feb 1689 daysLateO'Donnell NiallDirectorPPurchase+472.8K–––472.8K afterDerivative
Feb 21, 2023 (view filing)Feb 165 daysNovo Holdings A/S10% OwnerPPurchase+2.21M$3.17+$7.00M+48.9%6.72M after
Feb 21, 2023 (view filing)Feb 165 daysNovo Holdings A/S10% OwnerPPurchase+1.66M–––1.66M afterDerivative